ZNTL - Zentalis gives up gains from ovarian cancer candidate data; down 11%

2023-05-30 14:55:16 ET

• After closing up ~10.6% on Friday following the release of phase 1 data on ovarian cancer candidate azenosertib, Zentalis Pharmaceuticals ( NASDAQ: ZNTL ) has given back those gains.
• As of 250p ET, the stock is down 11% .
• Data released late on May 25 indicated improvements in objective response rate (ORR) and median progression free survival (mPFS), as well as signs of clinical activity.
• Azenosertib, a potential first-in-class WEE1 inhibitor, was given in combination with paclitaxel or carboplatin.
• When azenosertib was given with paclitaxel , the ORR was 50% and mPFS was 7.4 months. When given with carboplatin, the results were, respectively, 35.7% and 10.4 months.
• Seeking Alpha's Quant Rating has viewed Zentalis ( ZNTL ) as a hold since May 3.

For further details see: